Imperative Care begins CLEAR-IT study as peripheral thrombectomy moves from device adoption to evidence scrutiny
Imperative Care’s CLEAR-IT study could reshape peripheral thrombectomy standards. Read why its real-world data strategy matters now.
What Boston Scientific’s $14.5bn Penumbra buyout means for stroke and clot intervention markets
Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject […]